Table 3. Diagnosis prevalence of HD population according to sex.
Chronic condition | Male | Female | Total |
---|---|---|---|
Prevalence at t = 0 (time of HD diagnosis) | |||
Heart disease | 100.00 (406792) | 100.00 (359804) | 100.00 (766596) |
Hypertension | 64.97 (264306) | 74.69 (268721) | 69.53 (533027) |
High cholesterol | 32.50 (132213) | 23.52 (84640) | 28.29 (216853) |
Allergies | 14.51 (59013) | 21.16 (76149) | 17.63 (135162) |
COPD | 11.03 (44873) | 12.08 (43462) | 11.52 (88335) |
Diabetes | 11.66 (47426) | 10.12 (36401) | 10.93 (83827) |
Depression | 6.38 (25955) | 12.30 (44255) | 9.16 (70210) |
Osteoporosis | 4.13 (16800) | 14.81 (53307) | 9.14 (70107) |
Stroke | 8.81 (35834) | 9.06 (32596) | 8.93 (68430) |
Cancer | 6.87 (27934) | 7.26 (26122) | 7.05 (54056) |
Osteoarthritis | 5.70 (23193) | 8.20 (29496) | 6.87 (52689) |
Back pain | 5.26 (21409) | 6.39 (23005) | 5.79 (44414) |
Dementia | 1.39 (5665) | 2.58 (9277) | 1.95 (14942) |
Schizophrenia | 1.34 (5466) | 1.92 (6926) | 1.62 (12392) |
Joint disease | 1.34 (5455) | 1.55 (5580) | 1.44 (11035) |
Lifetime prevalencea | |||
Heart disease | 100.00 (406792) | 100.00 (359804) | 100.00 (766596) |
Hypertension | 77.71 (316100) | 85.11 (306224) | 81.18 (622324) |
High cholesterol | 51.12 (207983) | 37.94 (136502) | 44.93 (344485) |
Allergies | 25.24 (102687) | 32.99 (118701) | 28.88 (221388) |
COPD | 25.07 (101975) | 24.32 (87506) | 24.72 (189481) |
Osteoporosis | 12.11 (49269) | 33.35 (120002) | 22.08 (169271) |
Stroke | 21.15 (86021) | 22.12 (79606) | 21.60 (165627) |
Diabetes | 22.74 (92519) | 18.75 (67450) | 20.87 (159969) |
Depression | 15.87 (64542) | 25.33 (91156) | 20.31 (155698) |
Cancer | 20.38 (82923) | 17.92 (64485) | 19.23 (147408) |
Osteoarthritis | 12.63 (51361) | 16.47 (59268) | 14.43 (110629) |
Back pain | 11.52 (46846) | 13.43 (48332) | 12.42 (95178) |
Dementia | 6.34 (25806) | 10.25 (36890) | 8.18 (62696) |
Schizophrenia | 3.56 (14462) | 5.22 (18778) | 4.34 (33240) |
Joint disease | 4.26 (17330) | 3.73 (13436) | 4.01 (30766) |
Prevalence are reported as % (n).
aLifetime prevalence is to be understood in the sense that the HD diagnosed individual has been observed to obtain the diagnosis in the time period 1995–2015.